Crossmark

Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”

Published Online: 2018-03-30

Published Print: 2018-04-01

Authors

Kim, Sang-Tae

Park, Jeongbin https://orcid.org/0000-0002-9064-4912
Kim, Daesik

Kim, Kyoungmi

Bae, Sangsu https://orcid.org/0000-0003-3615-8566
Schlesner, Matthias https://orcid.org/0000-0002-5896-4086
Kim, Jin-Soo
License Information

Text and Data Mining valid from 2018-03-30

Version of Record valid from 2018-03-30
More Information

Article History

First Online: 30 March 2018

Competing interests

: J.-S.K. is a cofounder of and holds stocks in ToolGen, Inc., a company focused on therapeutic genome editing. All the other authors declare no competing financial interests.

Document is current